CONNECT-HF is a nationwide clinical trial for people who are leaving the hospital after receiving treatment for heart failure. Heart failure is one of the most common reasons for hospital stays in the United States. The goal of the CONNECT-HF Trial is to help improve care for people with heart failure, so that they can live healthier lives and have a better chance of staying out of the hospital.
CONNECT-HF is not testing a new medication. This means that people taking part in the trial will not have to take a certain medication. Instead, this trial will look at what kind of care and what kind of resources people with heart failure use after leaving the hospital. Researchers want to collect information from patients to find out what kind of support and care is the most helpful during a time that can be overwhelming to many people.
Who will take part in the trial?
8,000 people with heart failure, from 160 hospitals across the United States, will take part in the CONNECT-HF trial.
How long will the trial last?
People who choose to join the trial will take part for one year. They will be required to have four follow-up calls with the trial team, to tell them about their health and how they are feeling. People will be joining the trial, at different times, for a total of three years.
Why is this study being done?
Nearly 5.7 million people in the United States have heart failure.
Heart failure is one of the most common reasons for hospital stays in the United States, and nearly 1 in 4 patients who are in the hospital because of heart failure, end up in the hospital again within 30 days. The good news is that many hospital stays can be prevented.
However, in the past, plans to improve care for heart failure have not been used as much as they should. The CONNECT-HF researchers want to help figure out how to provide the best care possible to people with heart failure, to improve their health and to lower their number of hospital stays.
Patients with heart failure have a lot to keep up with once they go home from the hospital. Managing heart failure includes keeping up with medication, visiting the doctor regularly, making diet, exercise, and other lifestyle changes, and more. This can be overwhelming for patients, and those helping to take care of them, which is why researchers want to understand better ways to help patients manage heart failure in their daily lives.
What is the benefit of taking part in this trial?
There may not be a direct benefit in taking part in this trial. However, people taking part in the trial will be given tips, ideas, and resources that will help make it easier to manage heart failure. They will also learn more about heart failure, and certain lifestyle changes they can make to help improve their everyday lives.
What are the risks of taking part in this trial?
Because participants will not have to take a certain medication for this trial, the risks of taking part are low. There is a potential risk of loss of confidentiality of their information, but the trial team will make every effort to ensure this does not happen.
Who is running the CONNECT-HF trial?
CONNECT-HF is being run by Duke Clinical Research Institute (DCRI), a special division of Duke University that focuses on carrying out research to improve patient care. The trial is funded by an independent investigator grant to Duke from Novartis.
How was this trial designed?
The CONNECT-HF trial was designed to provide resources that will be helpful to people living with heart failure, and to collect information about how those resources are working. The CONNECT-HF trial team worked closely with a group of patient advisers, who all have heart failure, to gain their insights for making make the trial as patient-friendly and useful as possible.
1. Fonarow G. Reducing 30 Day Heart Failure Readmissions. 2016.